Ignite Creation Date:
2025-12-24 @ 5:24 PM
Ignite Modification Date:
2026-01-23 @ 6:05 AM
Study NCT ID:
NCT00475150
Status:
COMPLETED
Last Update Posted:
2017-02-15
First Post:
2007-05-16
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | View |
| None | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | View |
| None | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | View |
| None | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | View |
| None | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | View |
| None | de Novo Myelodysplastic Syndromes | View |
| None | Previously Treated Myelodysplastic Syndromes | View |
| None | Recurrent Adult Acute Myeloid Leukemia | View |
| None | Secondary Acute Myeloid Leukemia | View |
| None | Secondary Myelodysplastic Syndromes | View |
| None | Untreated Adult Acute Myeloid Leukemia | View |
Keywords: